Literature DB >> 11156936

Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells.

P Takacs1, S W Kauma, M M Sholley, S W Walsh, M J Dinsmoor, K Green.   

Abstract

Preeclampsia is a systemic disease of pregnancy characterized by maternal hypertension, proteinuria, and edema. These clinical pathological findings may be attributed to abnormalities in vascular endothelial activation secondary to increased oxidative stress. To test the hypothesis that increased circulating lipid peroxides in preeclamptic women activate vascular endothelial cells, we determined NF-kappaB transcriptional activity and ICAM-1 expression in human umbilical vein endothelial cells (HUVEC) cultured with plasma from women with severe preeclampsia (preeclamptic plasma, N = 12) or plasma from normal pregnancies (normal plasma, N = 12). Preeclamptic women had increased circulating lipid peroxides compared with normal pregnant women, as demonstrated by a 4.5-fold higher concentration of plasma malondialdehyde (PkB luciferase reporter construct transfected into HUVEC, preeclamptic plasma was found to up-regulate HUVEC NF-kappaB activity by 2.5-fold when compared with normal plasma (PkB activation in response to preeclamptic-plasma by 77% (PkB activation and ICAM-1 expression on HUVEC, which can be inhibited by vitamin E and N-acetyl-cysteine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156936     DOI: 10.1096/fj.00-0549fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  What causes endothelial cell activation in preeclamptic women?

Authors:  Scott W Walsh
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

2.  Sexual Dimorphisms of Preeclampsia-Dysregulated Transcriptomic Profiles and Cell Function in Fetal Endothelial Cells.

Authors:  Chi Zhou; Qin Yan; Qing-Yun Zou; Xin-Qi Zhong; Chanel T Tyler; Ronald R Magness; Ian M Bird; Jing Zheng
Journal:  Hypertension       Date:  2019-06-03       Impact factor: 10.190

3.  Activation of NF-κB in placentas of women with preeclampsia.

Authors:  John E Vaughan; Scott W Walsh
Journal:  Hypertens Pregnancy       Date:  2012-03-01       Impact factor: 2.108

4.  Genome-wide hypermethylation coupled with promoter hypomethylation in the chorioamniotic membranes of early onset pre-eclampsia.

Authors:  Travers Ching; Min-Ae Song; Maarit Tiirikainen; Janos Molnar; Marla Berry; Dena Towner; Lana X Garmire
Journal:  Mol Hum Reprod       Date:  2014-06-18       Impact factor: 4.025

5.  Expressions of nuclear factor-kappa B p50 and p65 and their significance in the up-regulation of intercellular cell adhesion molecule-1 mRNA in the nasal mucosa of allergic rhinitis patients.

Authors:  Shi Zhen Wang; Feng Mei Ma; Jian Dong Zhao
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-02       Impact factor: 2.503

6.  Plasma from preeclamptic women stimulates transendothelial migration of neutrophils.

Authors:  Scott W Walsh
Journal:  Reprod Sci       Date:  2008-12-15       Impact factor: 3.060

7.  MicroRNA-138 improves LPS-induced trophoblast dysfunction through targeting RELA and NF-κB signaling.

Authors:  Ailan Yin; Qian Chen; Mei Zhong; Bei Jia
Journal:  Cell Cycle       Date:  2021-02-08       Impact factor: 4.534

8.  Obese rats exhibit high levels of fat necrosis and isoprostanes in taurocholate-induced acute pancreatitis.

Authors:  Javier Pereda; Salvador Pérez; Javier Escobar; Alessandro Arduini; Miguel Asensi; Gaetano Serviddio; Luis Sabater; Luis Aparisi; Juan Sastre
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

9.  Serum NF-κBp65, TLR4 as Biomarker for Diagnosis of Preeclampsia.

Authors:  Zhao Litang; Wang Hong; Zhang Weimin; Tian Xiaohui; Sun Qian
Journal:  Open Med (Wars)       Date:  2017-12-02

10.  Landscape of transcriptional deregulations in the preeclamptic placenta.

Authors:  Daniel Vaiman; Rosamaria Calicchio; Francisco Miralles
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.